A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

NCT06857942 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether adding tirzepatide to ixekizumab improves skin-related quality of life in adults with moderate-to-severe plaque psoriasis who are also overweight or obese.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 200 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-03 · est. completion 2028-05

Where 41 sites · Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT06857942 ↗

Description as written by the study sponsor.

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC

Main thing measured	Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) (0,1)
Sponsor	Eli Lilly and Company
Conditions studied	Psoriasis, Overweight or Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06857942 ↗